Friday, November 13, 2026

Flow Traders Deploys Deep Learning in Live Trading as Retail Platforms Open AI-Powered Access Globally

Dutch market maker Flow Traders integrated deep learning into production trading systems as retail platforms BitMart and nof1.ai launched AI-powered features for individual traders. Google's Gemini 3 Pro and NVIDIA's 40% faster training benchmarks enable global deployment, while regulatory divergence—China's crypto ban versus Europe's Bittensor ETP approval—creates fragmented AI trading landscapes.

From our archive, published before source-traceability. How we work

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Flow Traders Deploys Deep Learning in Live Trading as Retail Platforms Open AI-Powered Access Globally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Flow Traders, the Amsterdam-based institutional market maker, deployed deep learning algorithms in live trading operations. The integration coincides with BitMart's AI trading features and nof1.ai's real capital access for retail users, marking institutional-retail convergence in algorithmic trading.

Google's Gemini 3 Pro provides computational infrastructure for pattern recognition across global markets. NVIDIA's latest benchmarks show 40% faster training times for trading models, reducing costs for institutions from New York to Singapore deploying similar systems.

Bitcoin's recent all-time high followed by sharp correction tested AI systems in real conditions across time zones. Platforms using deep learning for risk management showed 30% better drawdown control during volatility, according to performance data from deployed systems in Asia, Europe, and North America.

Regulatory divergence shapes deployment strategies. China's renewed cryptocurrency trading ban limits training data quality for AI systems targeting Asian markets, while Tether's credit rating downgrade affects stablecoin-based strategies globally. Europe's Bittensor ETP approval and the Federal Reserve's dovish policy shift create favorable conditions in Western markets.

Infrastructure costs remain prohibitive for individual traders. Deep learning models for market prediction require GPU clusters costing $50,000-$200,000 monthly for institutional-grade systems. Retail platforms address this through shared model access, allowing traders worldwide to use pre-trained networks without infrastructure investment.

The institutional-retail technology gap narrows faster than previous innovations. Transformer models for sentiment analysis, reinforcement learning for execution, and neural networks for volatility prediction—once exclusive to hedge funds with eight-figure budgets—now deploy on retail platforms from London to Tokyo. Cloud infrastructure and open-source models enable deployment across borders in months rather than the decades quantitative strategies required.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· January 13, 2026
    BitMart 2025 Annual Review: Building a More Complete Financial Infrastructure to Drive Long-Term Sustainable Growth
  2. [2]Press releaseGlobeNewswire· December 5, 2025
    CoinEx Research November 2025 Report: Painvember's Brutal Reality Check
  3. [3]News articleYahoo Finance· February 12, 2026
    Flow Traders 4Q and FY 2025 Results

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com